CA
NZ
UK
AU
IND
US
Josh A. Wetzel, VP and Chief Accounting Officer of Frontier Group Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing three open-market sales of common stock totaling 12,000 shares between November 5 and November 9, 2026.
Alexandre Clerc, SVP of Customers at Frontier Group Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 5,520 shares of common stock on November 5, 2026.
Robert Schroeter, SVP and Chief Marketing Officer of Frontier Group Holdings, Inc., filed a Form 4 on November 9, 2026, reporting the sale of 37,914 shares of common stock on November 5, 2026.
Trevor J. Stedke, Senior Vice President of Operations at Frontier Group Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 34,180 shares of common stock on November 6, 2026.
General Dynamics Corp Chairman and CEO Phebe N. Novakovic filed a Form 4 on November 9, 2026, disclosing the sale of 45,353 shares of General Dynamics common stock on November 5, 2026, across six transactions at weighted average prices ranging from $360.052 to $365.605 …
An amended ownership statement for Evelyn D'An, a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), was filed on November 9, 2026, correcting an administrative error in the previously reported exercise price of a stock option granted on November 6, 2026.
Director Edward Neugeboren of Matinas BioPharma Holdings, Inc. filed an amended ownership statement on November 9, 2026, correcting an administrative error in the reported exercise price of a stock option granted on November 6, 2026.
Simon van den Born, President of Marex Group Ltd, filed a Form 4 on November 9, 2026, disclosing the sale of 22,456 ordinary shares on November 5, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Finance of America Companies Inc. Chief Investment Officer Jeremy Prahm filed a Form 4 on November 9, 2026, disclosing the sale of 6,000 shares of Class A Common Stock on November 5, 2026, pursuant to a Rule 10b5-1 trading plan.
An amended ownership statement for Keith Murphy, a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), was filed on November 9, 2026, to correct the reported exercise price of a stock option granted on November 6, 2026.
Please wait processing your request...